Cardiogen vs SLU-PP-332
Side-by-side comparison of key properties, dosing, and research.
Anti-Aging & Longevity
CardiogenRecovery & RepairFat Loss & Metabolic
SLU-PP-332- Summary
- Cardiogen is a tetrapeptide bioregulator (Ala-Glu-Asp-Arg) developed by Professor Vladimir Khavinson. It is a tissue-specific bioregulator for the heart and myocardium, designed to normalize cardiomyocyte function and support cardiac tissue regeneration. Research has demonstrated cardioprotective effects, improved cardiac rhythm, and benefits in recovery from ischemic injury.
- SLU-PP-332 is a small molecule exercise mimetic that activates estrogen-related receptors ERRalpha and ERRdelta (ERRa/d), transcription factors that drive oxidative metabolism programs. In animal studies it significantly enhanced endurance capacity and metabolic fitness without exercise, mimicking many of the cardiovascular and metabolic adaptations of aerobic training.
- Half-Life
- Short (minutes); gene-regulatory effects persist longer
- Not established in humans; rodent pharmacokinetics suggest hours
- Admin Route
- SubQ, Oral
- Oral (research), Subcutaneous (research)
- Research
- —
- —
- Typical Dose
- 10 mg per day
- Not established for humans; rodent studies used ~100 mg/kg/day
- Frequency
- Daily for 10–30 days
- Once daily in rodent studies
- Key Benefits
- Cardioprotective effects on myocardial tissue
- Normalization of cardiomyocyte protein synthesis
- May improve cardiac rhythm and conduction
- Support for recovery from ischemic cardiac events
- Anti-aging effects on heart tissue
- Potential reduction in cardiac fibrosis
- Often combined with Epithalon for comprehensive cardiovascular longevity support
- Significant enhancement of aerobic endurance capacity
- Increases mitochondrial density and oxidative metabolism in muscle
- Promotes beneficial shift toward oxidative muscle fiber phenotype
- Improves cardiac efficiency and cardiovascular fitness markers
- Potential for obesity, metabolic syndrome, and heart failure treatment
- Exercise mimetic for populations unable to exercise (disability, frailty, disease)
- Side Effects
- Generally well tolerated in available research
- Mild injection site reactions
- No significant adverse cardiovascular events reported at standard doses
- Limited human data; all studies are preclinical (rodent)
- Unknown cardiovascular effects with long-term or high-dose use in humans
- Potential hormonal interactions via ERR pathway (ERRs modulate estrogen-related signaling)
- Off-target effects not fully characterized
- Stacks With
- —
- —